Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Istituto Di Ricerche Farmacologiche Mario Negri
Sponsor

Istituto Di Ricerche Farmacologiche Mario Negri

Italy Via Mario Negri 2, 20156 Milan, Italy

About the sponsor

Research activity centers on membranous nephropathy, primary membranous nephropathy, and idiopathic nephrotic syndrome, with additional work in end-stage kidney disease on chronic dialysis therapy and chronic kidney disease complicated by hyperkalemia.

  • Nephrotic syndrome
  • Anti-CD20-resistant kidney disease
  • Potassium management in CKD and dialysis

These studies include treatment strategies for proteinuria, relapse prevention, and electrolyte control in advanced renal disease.

About Specializations

Istituto Di Ricerche Farmacologiche Mario Negri runs clinical trials in conditions such as Glomerulonephritis membranous, Nephrotic syndrome, End stage renal disease, Dialysis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

11 clinical trials

Nephrotic syndrome

Recruiting

Obinutuzumab treatment for adults with frequently relapsing idiopathic nephrotic syndrome who are dependent on rituximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

End stage renal disease+1

Recruiting

Study of Patiromer to Allow Less Dietary Potassium Restrictions in Patients on Chronic Dialysis with Controlled Blood Potassium Levels

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Patiromer
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcarnitine hydrochloride
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Hormone receptor positive breast cancer+2

Not yet recruiting

Abemaciclib plus drug combination in women with early-stage hormone‑positive HER2‑negative breast cancer: phase II study to reduce chemotherapy and surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Cardiac arrest

Not yet recruiting

Study on the Safety of Argon and Oxygen Ventilation for Patients Resuscitated from Cardiac Arrest

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Argon
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Non-small cell lung cancer stage III

Not recruiting

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Glomerulonephritis membranous

Not recruiting

Study of Felzartamab for Patients with Membranous Nephropathy Resistant to Anti-CD20 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aminohippuric Acid
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Ovarian epithelial cancer stage IV+1

Not recruiting

Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Hyperkalaemia

Not recruiting

Study on Patiromer and Placebo for Managing Hyperkalemia in Non-Dialysis Patients with Chronic Kidney Disease Stages IIIB to V

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Glomerulonephritis membranous

Not recruiting

Study of Obinutuzumab for Patients with Primary Membranous Nephropathy Resistant or Intolerant to Rituximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.